Compare AKTX & LITB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AKTX | LITB |
|---|---|---|
| Founded | N/A | 2007 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Catalog/Specialty Distribution |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.4M | 57.1M |
| IPO Year | 2014 | 2013 |
| Metric | AKTX | LITB |
|---|---|---|
| Price | $9.88 | $3.07 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $33.50 | N/A |
| AVG Volume (30 Days) | ★ 77.2K | 5.6K |
| Earning Date | 05-14-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $14.50 |
| Revenue Next Year | N/A | $11.59 |
| P/E Ratio | ★ N/A | $10.96 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.12 | $1.63 |
| 52 Week High | $29.32 | $4.17 |
| Indicator | AKTX | LITB |
|---|---|---|
| Relative Strength Index (RSI) | 53.55 | 45.69 |
| Support Level | $9.20 | $2.82 |
| Resistance Level | $15.50 | $3.34 |
| Average True Range (ATR) | 1.30 | 0.18 |
| MACD | 0.14 | -0.01 |
| Stochastic Oscillator | 54.76 | 13.51 |
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) built around novel, proprietary payloads utilizing powerful biology to attack cancer. Its payload, PH1, targets RNA splicing by modulating the spliceosome, a complex machinery in the cell that converts pre-RNA into spliced RNA for translation into vital proteins for cell survival and growth. Its product pipeline is AKTX-101, which targets the Trop2 receptor on cancer cells and, with a proprietary linker, enables it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. and AKTX-102, an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen expressed across multiple solid tumors.
LightInTheBox Holding Co Ltd is a e-commerce company, providing a diverse range of affordable lifestyle products directly to consumers. Its brands include Ador, a women's fashion brand targeting women aged 35-55; the second is a golf apparel brand focusing on female golfers aged 35 and above; the third is a women's light party dress brand for the age group of 30 and above. It offers customers products through websites and mobile applications. The company operates and reviews its performance in two segments: Product sales which consisted of online retailing of consumer products and sales to third-party sellers, and Services which consisted of the provision of logistic services to companies and individual customers.